ClinicalTrials.gg
Active, not recruitingNCT05456867NIS durvalumabUpdated Mar 17, 2026

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

An observational study in NSCLC, Non-small-cell Lung Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 22 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by AstraZeneca · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Planned enrollment
42nd of 67
250 · median 350
Started
2022
with 13 others
Observational
67 of 210
10 open now
Primary completion
2026-11
later than 38 of 78 live
Registered
159th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 42nd largest by planned enrollment of the 67 observational ones that give a count, is one of 14 that started in 2022, is one of 67 observational ones, reaches primary completion later than 38 of the 78 other live ones, and was the 159th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab in this indication. Moreover, generation data on the safety and real world effectiveness of durvalumab after concurrent chemo-radiation therapy (cCRT) and subsequent chemo-radiation therapy (sCRT) in routine practice in the Russian Federation will be of high relevance.

The other important question that needs to be addressed is the duration of treatment with durvalumab and its' influence on the relevant outcomes. According to the Russian label, it is possible to continue treatment with durvalumab until disease progression, although current data from the PACIFIC trial provide the results on 12 months duration of durvalumab treatment. The real-world data about the duration of treatment with durvalumab in the Russian population and its' influence on various outcomes would be very important.

Among other goals, the current study is aimed to analyze factors influencing the effectiveness of durvalumab therapy in the real-world setting (e.g. duration of treatment, delays in the start of treatment with durvalumab after CRT over, early discontinuation due to any factors including AEs, etc.). The study also aims to elucidate treatment approaches after discontinuation from durvalumab (post-progression outcomes and treatment in case of discontinuation due to AEs). This study will support the understanding of described factors and will take and an attempt to optimize the treatment process to improve outcomes for patients

03

Conditions studied

  • NSCLC, Non-small-cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study may include all patients who have received the first dose of durvalumab prior to study participation.

To enter in the study, patients must have completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression. There is no fixed maximum duration for durvalumab treatment. Treatment with durvalumab continues until the physician determines that it is in the patient's best interest to stop therapy.

It is expected to recruit 300 patients from approximately 25 cites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:

  • Written obtained from the patient prior to performing any protocol-related procedures
  • Age ≥18 years at time of study entry
  • Patients must have or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer [AJCC] lung cancer edition 8)
  • Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression
  • Patients must have been treated with at least one dose of durvalumab

Exclusion criteria

Exclusion Criteria:

Any subject who meets any of the following criteria will not qualify for entry into the study:

  • Absence or missing of written form
  • Patients treated with durvalumab in clinical studies
  • Absence of essential data to obtain all necessary information
  • Confirmation that the subject was already included in this study before
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

This study also gives Durvalumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Safety of durvalumab in patients with unresectable locally advanced NSCLC without progression after CRT in routine practice of the Russian Federation.

    Time frame: Up to 54 month

  2. Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation.

    Time frame: Up to 54 month

  3. Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation separately for fix dose (1500mg every 4 weeks) and 10mg/kg every 2 weeks dosage.

    Time frame: Up to 54 month

  4. Number of irAEs

    Time frame: Up to 54 month

  5. Number of SAEs

    Time frame: Up to 54 month

  6. Number of grade 3-4 AEs

    Time frame: Up to 54 month

  7. Number of post discontinuation irAEs

    Time frame: Up to 54 month

  8. Number of AESIs

    Time frame: Up to 54 month

  9. Number of AEs which lead to discontinuation

    Time frame: Up to 54 month

  10. Time to pneumonitis [median, months]

    Time frame: Up to 54 month

  11. Distribution of pneumonitis grades

    Time frame: Up to 54 month

  12. Nature of pneumonitis by physician diagnosis [radiation or immune-related]

    Time frame: Up to 54 month

  13. Duration of pneumonitis [median, months]

    Time frame: Up to 54 month

07

Study locations

22 sites
  • Research Site
    Arkhangelsk, Russia
  • Research Site
    Chelyabinsk, Russia
  • Research Site
    Grozny, Russia
  • Research Site
    Irkutsk, Russia
  • Research Site
    Khanty-Mansiysk, Russia
  • Research Site
    Kostroma, Russia
  • Research Site
    Krasnodar, Russia
  • Research Site
    Krasnoyarsk, Russia
  • Research Site
    Moscow, Russia
  • Research Site
    Murmansk, Russia
  • Research Site
    Nizhny Novgorod, Russia
  • Research Site
    Novosibirsk, Russia
  • Research Site
    Perm, Russia
  • Research Site
    Saint Petersburg, Russia
  • Research Site
    Sochi, Russia
  • Research Site
    Surgut, Russia
  • Research Site
    Tomsk, Russia
  • Research Site
    Ufa, Russia
  • Research Site
    Vologda, Russia
  • Research Site
    Yaroslavl, Russia
  • Research Site
    Yekaterinburg, Russia
  • Research Site
    Yuzhno-Sakhalinsk, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Nov 2026, 53 months after the start.

Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 53 months is close to that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jul 13, 2022
StartActual
May 31, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05456867
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
May 31, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Mar 17, 2026

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion